Clinical trials: sponsored by Akeso
Hyperlipidemia
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
This is a randomized, double-blind, placebo-controlled phase 3 clinical study evaluating the long-term efficacy and safety of AK102 in patients with primary hypercholesterolemia and mixed hyperlipidemia.
- Trial name
- NCT05255458
- Testing
- AK102
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Akeso
Psoriasis
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT05096364
- Where
- 13 sites in China
- Volunteers
- 251 people
- Sponsor
- Akeso
Recurrent Cervical Cancer, Metastatic Cervical Cancer
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
This is a Phase 2, global, multicenter, open label, single arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated…
- Trial name
- NCT04380805
- Testing
- AK104
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Akeso
Plaque Psoriasis
Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis
This is a multiple-center, randomized, double-blind, placebo-controlled Phase IIb study to evaluate the efficacy and safety of AK101, an anti-IL-12/23 p40 antibody, when administered subcutaneously, in subjects with…
- Trial name
- NCT04173637
- Testing
- AK101
- Where
- 2 sites in China
- Volunteers
- 330 people
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a multicenter, single-arm open-label, phase II study to evaluate the anti-tumor activity, safety, PK and immunogenicity of AK105 (Anti-PD1 antibody) in patients with metastatic nasopharyngeal carcinoma who have progressed…
- Trial name
- NCT03866967
- Testing
- AK105
- Where
- 2 sites in China
- Volunteers
- 130 people
- Sponsor
- Akeso
Psoriasis, Skin Diseases
A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind, placebo-controlled, multicenter phase III clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT06066125
- Testing
- AK111
- Where
- 34 sites in China
- Volunteers
- 351 people
- Sponsor
- Akeso
Solid Tumor, Adult
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.
- Trial name
- NCT05559541
- Testing
- AK119, AK104
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Akeso
Classic Hodgkin Lymphoma
A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma
This is a phase I/II study. All subjects are patients diagnosed with relapse or refractory (R/R) classic Hodgkin lymphoma (cHL) and has progressed on treatment with PD-1/L1 inhibitor therapy.
- Trial name
- NCT06642792
- Testing
- AK129, AK117
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Akeso
Higher-risk Myelodysplastic Syndromes
A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic…
- Trial name
- NCT06196203
- Testing
- AK117, Azacitidine
- Where
- 15 sites in United States, China
- Volunteers
- 90 people
- Sponsor
- Akeso
Psoriasis, Skin Diseases
To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis
This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT06061471
- Testing
- AK111
- Where
- 11 sites in China
- Volunteers
- 454 people
- Sponsor
- Akeso
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
- Trial name
- NCT06756126
- Testing
- AK120
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Akeso
Pancreatic Cancer
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
This study is a multicenter, open-label, phase II study to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activities of AK104，a PD-1/CTLA-4 bispecific antibody, in…
- Trial name
- NCT05859750
- Testing
- AK104, Gemcitabine, Nab-Paclitaxel
- Where
- 7 sites in China
- Volunteers
- 78 people
- Sponsor
- Akeso
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of AK120 in Subjects With Moderate to Severe Atopic Dermatitis
This is a multicenter, randomized, open label phase II clinical study to evaluate the safety and efficacy of AK120 in the treatment of subjects with moderate to severe atopic dermatitis.
- Trial name
- NCT06092762
- Testing
- AK120
- Where
- 26 sites in China
- Volunteers
- 180 people
- Sponsor
- Akeso
Advanced Malignant Tumors
AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of AK137 in patients with advanced malignant tumors.
- Trial name
- NCT06691360
- Testing
- AK137
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Akeso
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06601335
- Testing
- AK117 in combination with AK112
- Where
- 2 sites in China
- Volunteers
- 510 people
- Sponsor
- Akeso
Cervical Cancer
AK104 in Neoadjuvant Treatment of Cervical Cancer
Phase II open label study to evaluate the safety and efficacy of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) in neoadjuvant treatment of cervical cancer.
- Trial name
- NCT05227651
- Testing
- AK104
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Akeso
Healthy Subjects (HS)
A Study Evaluating the Single Subcutaneous Injection of Ebronucimab in Chinese Healthy Male Subjects
This is a phase I clinical study to evaluate the pharmacokinetics (PK) similarity of single dose subcutaneous injection of Ebronucimab with different production processes in Chinese healthy male subjects.
- Trial name
- NCT06641388
- Testing
- Ebronucimab
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Akeso
Nasopharyngeal Carcinoma
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
This is a single-arm, open-label, multicenter, phase II study to evaluate the anti-tumor activity, PK and immunogenicity of AK104 in patients with metastatic nasopharyngeal carcinoma who have progressed after at least 2 prior…
- Trial name
- NCT04220307
- Testing
- AK104
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Akeso
Locally Advanced Cervical Carcinoma
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
This study is to evaluate the efficacy and safety of AK104 plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer
- Trial name
- AK104-305 (NCT05235516)
- Testing
- AK104, EBRT, BT
- Where
- 9 sites in China
- Volunteers
- 636 people
- Sponsor
- Akeso